BioTech
Mixed study results for MorphoSys blood-cancer drug raise questions about approval
LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug
Andrew Joseph and Adam Feuerstein
November 21, 2023